In pilot clinical studies using patient serum samples assayed by surface plasmon resonance (SPR), SubB2M detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers.
“SubB2M is potentially one of the most exciting breakthroughs in cancer diagnostics that I have seen in 40 years of medical research."
Not much $ but the news will put it back on the buy side and watch this space lists.
In pilot clinical studies using patient serum samples assayed by...
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
0.070(12.6%) |
Mkt cap ! $66.16M | |||
| Open | High | Low | Value | Volume |
| 62.0¢ | 62.5¢ | 58.0¢ | $171.1K | 280.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2953 | 62.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 25000 | 2 |
View Market Depth
| Last trade - 13.14pm 20/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |